99MTC-EDDA/HYNIC-IPSMA AS A RADIOPHARMACEUTICAL FOR DETECTING THE OVEREXPRESSION OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN

This invention relates to a new radiopharmaceutical inhibitor of the prostate-specific membrane antigen (iPSMA) containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing the molecule lipophilicity for coupling to hydrophobic sites of the PSMA, combined with conventional use...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SANTOS CUEVAS, Clara Leticia, AZORIN VEGA, Erika Patricia, OCAMPO GARCIA, Blanca Eli, JIMENEZ MANCILLA, Nallely Patricia, LUNA GUTIERREZ, Myrna Alejandra, FERRO FLORES, Guillermina
Format:	Patent
Sprache:	eng ; hun
Schlagworte:	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This invention relates to a new radiopharmaceutical inhibitor of the prostate-specific membrane antigen (iPSMA) containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing the molecule lipophilicity for coupling to hydrophobic sites of the PSMA, combined with conventional use of HYNIC as a chelating agent for 99mTc radiometal, where ethylenediamine diacetic acid (EDDA) is used to complete the radiometal coordination sphere. The new 99mTc-EDDA/HYNIC-iPSMA radiopharmaceutical detects, with high affinity and sensitivity in vivo, the PSMA protein overexpressed in prostate cancer cells by SPECT molecular imaging in nuclear medicine.The purpose of this invention is to provide a new specific radiopharmaceutical (molecular target radiopharmaceutical) of SPECT with high sensitivity for detection of tumors with PSMA over-expression.